Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBL0621)

PURPOSE: ABT-751 is an orally bioavailable sulfonamide that binds the colchicine site of beta-tubulin, thus inhibiting microtubule polymerizaton. A prior phase I study established the recommended dose in children with solid tumors as 200 mg/m(2) PO daily × 7 days every 21 days and subjects with neur...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Pediatr Blood Cancer
Päätekijät: Fox, Elizabeth, Mosse', Yael P., Meany, Holly M., Gurney, James G., Khanna, Geetika, Jackson, Hollie A., Gordon, Gary, Shusterman, Suzanne, Park, Julie R., Cohn, Susan L., Adamson, Peter C., London, Wendy B., Maris, John M., Balis, Frank M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2013
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5127168/
https://ncbi.nlm.nih.gov/pubmed/24347462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24900
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia